Subscribe to our newsletter to receive the latest product updates and special offers

HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

SRZN

Surrozen Inc

Last Close
May 03 • 04:00PM ET
10.00
Dollar change
-0.10
Percentage change
-0.99 		%
Held by: VTI VXF DCOR DFAT
Index- P/E- EPS (ttm)-10.25 Insider Own39.89% Shs Outstand2.06M Perf Week11.36%
Market Cap32.00M Forward P/E- EPS next Y-2.85 Insider Trans43.52% Shs Float1.92M Perf Month-11.74%
Income-43.04M PEG- EPS next Q-4.25 Inst Own30.42% Short Float1.88% Perf Quarter13.64%
Sales0.00M P/S- EPS this Y56.92% Inst Trans44.36% Short Ratio2.07 Perf Half Y63.40%
Book/sh18.39 P/B0.54 EPS next Y68.99% ROA-63.52% Short Interest0.04M Perf Year8.40%
Cash/sh11.26 P/C0.89 EPS next 5Y29.90% ROE-75.55% 52W Range4.50 - 16.19 Perf YTD6.38%
Dividend Est.- P/FCF- EPS past 5Y- ROI-110.88% 52W High-38.23% Beta0.89
Dividend TTM- Quick Ratio5.75 Sales past 5Y-33.33% Gross Margin77.27% 52W Low122.22% ATR (14)1.02
Dividend Ex-Date- Current Ratio5.75 EPS Y/Y TTM-37.28% Oper. Margin0.00% RSI (14)47.19 Volatility11.62% 9.92%
Employees42 Debt/Eq0.09 Sales Y/Y TTM-100.00% Profit Margin- Recom1.00 Target Price33.00
Option/ShortNo / Yes LT Debt/Eq0.02 EPS Q/Q-1018.12% Payout- Rel Volume0.04 Prev Close10.10
Sales Surprise- EPS Surprise-15.25% Sales Q/Q-100.00% EarningsNov 08 AMC Avg Volume17.44K Price10.00
SMA200.73% SMA50-15.08% SMA2008.20% Trades Volume736 Change-0.99%
Date Action Analyst Rating Change Price Target Change
Oct-11-21Initiated BofA Securities Buy $11
Sep-15-21Initiated Guggenheim Buy $20
Sep-07-21Initiated Stifel Buy $19
Apr-14-24 12:52PM
10 Buy-Rated Stocks with Latest Insider Purchases
(Insider Monkey)
Apr-03-24 08:40AM
Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis
(GlobeNewswire) +13.41%
Apr-01-24 08:30AM
Surrozen Announces up to $192.5 Million Private Placement of Securities Priced At-the-Market Under Nasdaq Rules
(GlobeNewswire) -35.71%
08:30AM
Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043
(GlobeNewswire)
Jan-18-24 09:58AM
Surrozen stops IBD program due to dose concerns and competition
(FierceBiotech.com) -5.53%
08:30AM Loading…
08:30AM
Surrozen Provides Corporate Update on Clinical Programs
(GlobeNewswire)
Dec-14-23 05:52AM
SRZN Stock Earnings: Surrozen Misses EPS for Q1 2023
(InvestorPlace) +9.33%
05:51AM
SRZN Stock Earnings: Surrozen Beats EPS for Q2 2023
(InvestorPlace)
Nov-08-23 04:05PM
Surrozen Provides Third Quarter 2023 Financial Results
(GlobeNewswire)
Aug-09-23 04:05PM
Surrozen Provides Second Quarter 2023 Financial Results
(GlobeNewswire) +5.52%
Jun-05-23 08:30AM
Surrozen Publishes Study in Nature Communications Demonstrating the Promise of a Fzd4 Wnt Antibody in Treating Ischemic Stroke
(GlobeNewswire)
May-10-23 04:05PM
Surrozen Provides First Quarter 2023 Financial Results and Corporate and Pipeline Updates
(GlobeNewswire)
Apr-05-23 08:30AM
Surrozen Strengthens Board of Directors with the Appointment of Eric Bjerkholt
(GlobeNewswire)
Mar-28-23 04:59AM
Surrozen, Inc. (NASDAQ:SRZN) Q4 2022 Earnings Call Transcript
(Insider Monkey) -8.52%
Mar-22-23 04:01PM
Surrozen Provides Fourth Quarter and Full Year 2022 Financial Results and Update on Clinical Pipeline and Corporate Progress
(GlobeNewswire)
04:30PM Loading…
Mar-20-23 04:30PM
Surrozen To Report Fourth Quarter and Full Year 2022 Financial Results and Provide a Corporate Update on March 22, 2023
(GlobeNewswire)
Jan-04-23 04:41PM
Surrozen to Present at the 41st Annual J.P. Morgan Healthcare Conference
(GlobeNewswire)
Nov-14-22 04:30PM
Surrozen Reports Third Quarter 2022 Financial Results and Provides Corporate Update
(GlobeNewswire)
Oct-10-22 08:00AM
Surrozen Presents Data on Two Lead Therapeutic Candidates at United European Gastroenterology (UEG) Week
(GlobeNewswire)
Oct-06-22 08:00AM
Surrozen Announces Strategic Partnership with Boehringer Ingelheim to Develop Wnt Agonist SZN-413 for People with Retinal Diseases
(GlobeNewswire)
Sep-26-22 08:00AM
Surrozen Publishes Study in Translational Vision Science and Technology Demonstrating the Promise of SZN-413 in Preclinical Models of Diabetic Retinopathy
(GlobeNewswire)
Aug-11-22 08:00AM
Surrozen Reports Second Quarter 2022 Financial Results
(GlobeNewswire)
Jun-27-22 10:34AM
What Is The Ownership Structure Like For Surrozen, Inc. (NASDAQ:SRZN)?
(Simply Wall St.)
Jun-13-22 08:00AM
Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-043 for Severe Alcoholic Hepatitis
(GlobeNewswire)
May-24-22 08:00AM
Surrozen Presents Data on Lead Therapeutic Candidates at Digestive Disease Week (DDW)
(GlobeNewswire) -5.75%
May-18-22 08:00AM
Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-1326 for Moderate to Severe Ulcerative Colitis
(GlobeNewswire) +7.29%
May-16-22 08:00AM
Surrozen Publishes Article in Cellular and Molecular Gastroenterology and Hepatology Demonstrating that SZN-1326, a Selective Wnt Mimetic, Stimulated Robust Colon Epithelial Regeneration and Ameliorated Colitis in an Acute Model of Inflammatory Bowel Disease (IBD)
(GlobeNewswire)
May-11-22 08:00AM
Surrozen Reports First Quarter 2022 Financial Results
(GlobeNewswire) -8.74%
May-05-22 08:00AM
Surrozen to Present at the BofA Securities 2022 Healthcare Conference
(GlobeNewswire) -12.88%
May-02-22 08:00AM
Surrozen Presents Data Supporting Potential of SZN-413 for the Treatment of Diabetic Retinopathy at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
(GlobeNewswire)
08:00AM Loading…
Mar-24-22 08:00AM
Surrozen Reports Fourth Quarter and Full Year 2021 Financial Results
(GlobeNewswire) -6.03%
Jan-20-22 09:00AM
Heartland Express, Inc. Reports Fourth Quarter and Annual Financial Results which includes All-Time Record High Annual Earnings Per Share
(GlobeNewswire) -7.62%
Jan-10-22 08:00AM
Surrozen Announces Key 2022 Milestones for Lead Programs and Acceleration of Research Pipeline
(GlobeNewswire)
Jan-05-22 08:00AM
Surrozen to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference
(GlobeNewswire)
Nov-15-21 04:00PM
Surrozen Reports Third Quarter 2021 Financial Results
(GlobeNewswire)
08:00AM
Surrozen to Present at The Piper Sandler 33rd Annual Healthcare Conference
(GlobeNewswire)
08:00AM
Surrozen Presents Data Supporting Potential of SZN-043 at The Liver Meeting 2021, the Annual Meeting of the American Association for the Study of Liver Diseases
(GlobeNewswire)
Nov-11-21 10:51AM
How Many Surrozen, Inc. (NASDAQ:SRZN) Shares Do Institutions Own?
(Simply Wall St.) +19.50%
Nov-05-21 08:00AM
Surrozen to Present at The Stifel 2021 Virtual Healthcare Conference
(GlobeNewswire)
Oct-05-21 04:30PM
Surrozen Presented Data Supporting Potential of SZN-1326 at the 2021 United European Gastroenterology Week
(GlobeNewswire) -5.75%
Sep-23-21 08:30AM
Surrozen Announces Appointment of Liz Nguyen as Vice President and Head of Human Resources
(GlobeNewswire) -9.07%
Aug-11-21 05:30PM
Surrozen Debuts as Publicly Traded Leader in Wnt Biology and Tissue Regeneration
(GlobeNewswire)
Surrozen, Inc. is a clinical stage biotechnology company. It engages in the business of discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. The company was founded by K. Christopher Garcia and Roeland Nusse on August 12, 2015 and is headquartered in South San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
COLUMN GROUP III GP, LP10% OwnerApr 04 '24Buy15.50193,5482,999,994332,885Apr 08 04:23 PM
Kutzkey TimDirectorApr 04 '24Buy15.50193,5482,999,994332,885Apr 08 04:24 PM
open in screener | open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Open in Screener

TNYA

Tenaya Therapeutics Inc

Last Close
May 03 • 04:00PM ET
4.68
Dollar change
+0.06
Percentage change
1.30 		%
TNYA Tenaya Therapeutics Inc daily Stock Chart
Held by: VTI IWM VXF IWN VTWO HRTS IWC AVSC FESM VTWV
IndexRUT P/E- EPS (ttm)-1.72 Insider Own20.73% Shs Outstand68.33M Perf Week8.58%
Market Cap367.47M Forward P/E- EPS next Y-1.81 Insider Trans37.18% Shs Float62.24M Perf Month2.18%
Income-124.08M PEG- EPS next Q-0.42 Inst Own45.46% Short Float5.41% Perf Quarter2.86%
Sales0.00M P/S- EPS this Y-3.57% Inst Trans-5.76% Short Ratio6.52 Perf Half Y152.97%
Book/sh2.04 P/B2.29 EPS next Y-4.20% ROA-55.21% Short Interest3.37M Perf Year-20.81%
Cash/sh1.33 P/C3.51 EPS next 5Y- ROE-64.83% 52W Range1.66 - 8.09 Perf YTD44.44%
Dividend Est.- P/FCF- EPS past 5Y-27.43% ROI-84.11% 52W High-42.16% Beta2.62
Dividend TTM- Quick Ratio4.91 Sales past 5Y0.00% Gross Margin- 52W Low181.93% ATR (14)0.32
Dividend Ex-Date- Current Ratio4.91 EPS Y/Y TTM38.34% Oper. Margin0.00% RSI (14)52.11 Volatility6.43% 6.13%
Employees140 Debt/Eq0.09 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price19.43
Option/ShortYes / Yes LT Debt/Eq0.06 EPS Q/Q27.78% Payout- Rel Volume0.18 Prev Close4.62
Sales Surprise- EPS Surprise7.79% Sales Q/Q- EarningsMar 18 AMC Avg Volume516.03K Price4.68
SMA204.59% SMA50-7.06% SMA20026.58% Trades Volume91,739 Change1.30%
Date Action Analyst Rating Change Price Target Change
Nov-30-23Initiated Leerink Partners Outperform $7
Jun-15-22Initiated H.C. Wainwright Buy $25
May-02-24 05:00PM
Tenaya Therapeutics to Highlight Growing Capabilities in Capsid Engineering, Gene Editing and Manufacturing at the American Society of Gene and Cell Therapy 27th Annual Meeting
(GlobeNewswire)
Mar-26-24 07:19AM
20 Countries with the Highest Heart Disease Deaths Per Capita
(Insider Monkey)
Mar-20-24 05:32AM
Tenaya Therapeutics Inc Reports Full Year and Q4 2023 Financial Results
(GuruFocus.com) +8.17%
Mar-18-24 10:53PM
TNYA Stock Earnings: Tenaya Therapeutics Beats EPS for Q4 2023
(InvestorPlace)
04:05PM
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
(GlobeNewswire)
08:30AM Loading…
08:30AM
Tenaya Therapeutics Announces Publication of TN-401 Gene Therapy Preclinical Data in Nature Communications Medicine
(GlobeNewswire)
Feb-29-24 03:02AM
14 Stocks With Heavy Insider Buying In 2024
(Insider Monkey)
Feb-27-24 04:30PM
Tenaya Therapeutics to Participate in Upcoming March Investor Conferences
(GlobeNewswire)
Feb-26-24 09:55AM
Should You Buy Tenaya Therapeutics, Inc. (TNYA) After Golden Cross?
(Zacks) +9.00%
08:30AM
Tenaya Therapeutics Announces Publication of Preclinical HDAC6 Inhibitor Data for Heart Failure with Preserved Ejection Fraction in Nature Communications
(GlobeNewswire)
Feb-09-24 09:55AM
Wall Street Analysts Think Tenaya Therapeutics, Inc. (TNYA) Could Surge 273.1%: Read This Before Placing a Bet
(Zacks) +10.72%
Feb-08-24 08:00AM
Tenaya Therapeutics Announces Pricing of Underwritten Offering
(GlobeNewswire) +16.06%
Jan-26-24 12:00PM
Tenaya Therapeutics, Inc. (TNYA) Upgraded to Strong Buy: Here's Why
(Zacks)
Jan-03-24 08:30AM
Tenaya Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference
(GlobeNewswire) -5.28%
Nov-21-23 04:30PM
Tenaya Therapeutics to Participate at the 35th Annual Piper Sandler Healthcare Conference
(GlobeNewswire)
04:05PM Loading…
Nov-08-23 04:05PM
Tenaya Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
(GlobeNewswire)
Oct-26-23 08:30AM
Tenaya Therapeutics Announces FDA Clearance to Begin Clinical Testing of TN-401 Gene Therapy for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy
(GlobeNewswire) -5.67%
Oct-09-23 08:30AM
Tenaya Therapeutics Presents Encouraging New Clinical and Preclinical Data from HDAC6 Inhibitor Program TN-301 for the Potential Treatment of Heart Failure with Preserved Ejection Fraction at the 2023 HFSA Annual Scientific Meeting
(GlobeNewswire)
Oct-05-23 08:30AM
Tenaya Therapeutics Doses First Patient in the MyPeak-1 Phase 1b Clinical Trial of TN-201 for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy
(GlobeNewswire)
Oct-02-23 05:30PM
Tenaya Therapeutics Publishes Preclinical Data in Circulation Highlighting the Clinical Potential of Cellular Reprogramming for Cardiac Regeneration
(GlobeNewswire)
Sep-21-23 04:05PM
Tenaya Therapeutics to Present Data for TN-301 and TN-201 at Upcoming Medical Conferences
(GlobeNewswire) +6.06%
Aug-31-23 04:05PM
Tenaya Therapeutics to Participate at the 21st Annual Morgan Stanley Global Healthcare Conference
(GlobeNewswire) -5.38%
Aug-09-23 04:05PM
Tenaya Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
(GlobeNewswire)
Aug-02-23 04:05PM
Tenaya Therapeutics to Participate at the 43rd Annual Canaccord Genuity Growth Conference
(GlobeNewswire)
May-30-23 09:06AM
With 35% stake, Tenaya Therapeutics, Inc. (NASDAQ:TNYA) seems to have captured institutional investors' interest
(Simply Wall St.)
May-15-23 09:55AM
Wall Street Analysts Believe Tenaya Therapeutics, Inc. (TNYA) Could Rally 217.58%: Here's is How to Trade
(Zacks)
May-11-23 08:50AM
Tenaya Therapeutics, Inc. (TNYA) Is a Great Choice for 'Trend' Investors, Here's Why
(Zacks) +7.65%
May-10-23 04:19PM
Tenaya Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
(GlobeNewswire)
May-03-23 08:00AM
Tenaya Highlights Growing Capabilities in AAV Manufacturing, Capsid Engineering and Expansion into Gene Editing with Six Abstracts Accepted for Presentation at the ASGCT 26th Annual Meeting
(GlobeNewswire) +12.36%
07:09AM
We Think Tenaya Therapeutics (NASDAQ:TNYA) Needs To Drive Business Growth Carefully
(Simply Wall St.)
07:50AM Loading…
May-02-23 07:50AM
Tenaya Therapeutics Receives FDA Fast Track Designation for TN-201
(GlobeNewswire) -11.30%
Apr-25-23 06:35AM
The 7 Best Biotech Stocks for Personalized Medicine Investors
(InvestorPlace) -5.77%
Apr-23-23 04:02PM
3 Penny Stocks to Buy for 100% Returns
(InvestorPlace)
Apr-21-23 04:05PM
Tenaya Therapeutics to Participate at Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
(GlobeNewswire) +22.79%
Apr-20-23 02:46PM
Why This Nasdaq Stock Caught Fire This Week
(Motley Fool) +26.08%
Apr-19-23 11:36AM
These 2 Strong Buy Penny Stocks Could Rally to $40 (or More), Says Piper Sandler
(TipRanks) +17.16%
Mar-08-23 04:01PM
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
(GlobeNewswire) -6.96%
Feb-07-23 05:17PM
Tenaya Therapeutics to Participate in Upcoming Investor Conferences
(GlobeNewswire)
Jan-26-23 12:00PM
Tenaya Therapeutics, Inc. (TNYA) Upgraded to Buy: Here's What You Should Know
(Zacks)
Jan-09-23 07:00AM
Tenaya Therapeutics Announces TN-201 IND Clearance and Anticipated 2023 Milestones
(GlobeNewswire)
Dec-21-22 06:12AM
Insiders who placed huge bets on Tenaya Therapeutics, Inc. (NASDAQ:TNYA) earlier this year would be disappointed with the 23% drop
(Simply Wall St.)
Dec-07-22 04:30PM
Tenaya Therapeutics Appoints Amy Burroughs to Board of Directors
(GlobeNewswire)
Dec-02-22 06:36PM
IRobot and Acrivon Stock See Action From Activist Investors
(Barrons.com)
Nov-28-22 08:30AM
Tenaya Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for its Gene Therapy for Genetic Arrhythmogenic Right Ventricular Cardiomyopathy
(GlobeNewswire) +7.11%
Nov-24-22 05:54AM
Here's Why Tenaya Therapeutics (NASDAQ:TNYA) Must Use Its Cash Wisely
(Simply Wall St.)
Nov-23-22 09:00AM
Tenaya Therapeutics to Participate in Upcoming Piper Sandler 34th Annual Healthcare Conference
(GlobeNewswire)
Nov-21-22 05:45PM
Tenaya Therapeutics Announces Closing of Public Offering
(GlobeNewswire)
Nov-17-22 12:39AM
Tenaya Therapeutics Announces Pricing of Public Offering
(GlobeNewswire) -21.63%
Nov-16-22 04:01PM
Tenaya Therapeutics Announces Proposed Public Offering
(GlobeNewswire) +8.87%
Nov-10-22 04:05PM
Tenaya Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
(GlobeNewswire) +6.81%
Nov-04-22 08:00AM
Tenaya Therapeutics to Present Preclincial Study Data from TN-301 Program at the American Heart Association Scientific Sessions 2022
(GlobeNewswire) -17.87%
Oct-14-22 06:12AM
Tenaya Therapeutics, Inc.'s (NASDAQ:TNYA) 17% loss last week hit both individual investors who own 40% as well as institutions
(Simply Wall St.)
Oct-04-22 08:30AM
Tenaya Therapeutics to Present Preclinical Data on Its Novel Engineered AAV Capsids for Cardiac Gene Delivery at the ESGCT 29th Annual Congress
(GlobeNewswire)
Sep-29-22 08:00AM
Tenaya Therapeutics to Participate in Inaugural Hypertrophic Cardiomyopathy Medical Societys 2022 Scientific Sessions
(GlobeNewswire) -10.42%
07:45AM
Tenaya Therapeutics to Participate in Upcoming October Investor and Industry Conferences
(GlobeNewswire)
Sep-26-22 09:21AM
10 Best Biotech Stocks Under $10
(Insider Monkey)
Sep-15-22 09:39AM
Harvard Universitys Latest Portfolio: 10 Best Biotech Stock Picks
(Insider Monkey)
Sep-06-22 04:05PM
Tenaya Therapeutics to Participate in Upcoming September Investor Conferences
(GlobeNewswire) -7.24%
08:00AM
Tenaya Therapeutics Announces FDA Clearance of Investigational New Drug Application and Initiation of Phase 1 Safety Study for TN-301, an HDAC6 Inhibitor for Heart Failure with Preserved Ejection Fraction
(GlobeNewswire)
Aug-16-22 09:55AM
Does Tenaya Therapeutics, Inc. (TNYA) Have the Potential to Rally 368% as Wall Street Analysts Expect?
(Zacks) -7.50%
Aug-10-22 04:01PM
Tenaya Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
(GlobeNewswire)
Jul-06-22 02:00PM
Tenaya Therapeutics Publishes Preclinical Data in Science Translational Medicine Detailing Discovery of HDAC6 Inhibitor for Treatment of Heart Failure
(GlobeNewswire)
Jun-16-22 08:00AM
Tenaya Therapeutics Launches Operations of New Genetic Medicines Manufacturing Center to Support the Development of Potentially First-In-Class Cardiovascular Therapeutics
(Business Wire)
May-20-22 08:30AM
Tenaya Therapeutics to Present Preclinical Data on TN-301 HDAC6 Inhibitor at European Society of Cardiology Heart Failure 2022 Conference
(Business Wire) +18.33%
May-11-22 04:09PM
Tenaya Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
(Business Wire) -12.00%
May-07-22 09:38AM
We're Not Very Worried About Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Rate
(Simply Wall St.)
May-03-22 08:00AM
Tenaya Therapeutics to Present Preclinical Data on Gene Therapy Programs and Platform Capabilities at the American Society of Gene and Cell Therapy 25th Annual Meeting
(Business Wire)
Apr-28-22 08:00AM
Tenaya Therapeutics to Present Preclinical Data on TN-401 PKP2 Gene Therapy Program at Heart Rhythm 2022
(Business Wire) +5.34%
Mar-24-22 08:30AM
Tenaya Therapeutics to Participate in Upcoming Investor Conferences
(Business Wire) +12.51%
Mar-23-22 04:05PM
Tenaya Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Updates
(Business Wire) -5.76%
Feb-08-22 12:01PM
Why Earnings Season Could Be Great for Tenaya Therapeutics (TNYA)
(Zacks)
Feb-04-22 01:03PM
What Is The Ownership Structure Like For Tenaya Therapeutics, Inc. (NASDAQ:TNYA)?
(Simply Wall St.) +7.56%
Jan-31-22 08:00AM
Tenaya Therapeutics to Participate in Upcoming Investor Conferences
(Business Wire) +14.40%
Jan-10-22 08:00AM
Tenaya Therapeutics Provides 2022 Business Updates
(Business Wire) -6.86%
Dec-23-21 12:38PM
Rtw Investments, Lp Buys Thermo Fisher Scientific Inc, Penumbra Inc, Tenaya Therapeutics Inc, ...
(GuruFocus.com)
Dec-22-21 04:05PM
Tenaya Therapeutics Appoints Karah Parschauer, J.D., to Its Board of Directors and Joanna Auch as Senior Vice President of People and Culture
(Business Wire) +8.98%
Dec-17-21 10:06AM
Harvard University Stock Portfolio: 8 Latest Stock Picks
(Insider Monkey)
Nov-22-21 08:00AM
Tenaya Therapeutics Announces the Addition of Dr. June Lee to its Board of Directors
(Business Wire) -8.27%
Nov-19-21 08:00AM
Tenaya Therapeutics to Participate in Upcoming Piper Sandler 33rd Annual Virtual Healthcare Conference
(Business Wire)
Nov-10-21 04:05PM
Tenaya Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates
(Business Wire)
Nov-05-21 08:36PM
Gene Therapy Is a Huge Opportunity. It Pays to be Patient.
(Barrons.com)
03:30AM
Testing May Take Awhile, but Gene Therapy Is Poised to Tackle Mass Diseases
(Barrons.com)
Nov-03-21 03:41PM
We're Not Very Worried About Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Rate
(Simply Wall St.)
Oct-12-21 06:05PM
Tenaya Therapeutics to Present Preclinical Data on Its Gene Therapy Programs at the ESGCT 28th Annual Congress
(Business Wire) -6.02%
Oct-08-21 12:42PM
Most of this year's flood of new Bay Area public companies are 'under water'
(American City Business Journals)
Oct-04-21 10:54AM
Buy These 3 New Stocks Before They Jump Over 60%, Say Analysts
(TipRanks) +5.78%
Sep-30-21 06:02PM
Tenaya Therapeutics to Participate in Upcoming Investor and Industry Conferences
(Business Wire)
Sep-08-21 04:00PM
Tenaya Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Updates
(Business Wire)
Aug-31-21 08:00AM
Tenaya Therapeutics to Present at Morgan Stanley 19th Annual Global Healthcare Conference
(Business Wire) -21.45%
Aug-03-21 04:05PM
Tenaya Therapeutics Announces Closing of Upsized Initial Public Offering and Exercise in Full of the Underwriters Option to Purchase Additional Shares
(Business Wire)
Jul-30-21 05:28PM
Dole Drops in IPO. 7 Biotechs Went Public, Too.
(Barrons.com)
Jul-29-21 11:46PM
Tenaya Therapeutics Announces Pricing of Upsized Initial Public Offering
(Business Wire)
Tenaya Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapeutics for cardiovascular diseases. It operates through its product platforms: gene therapy, cellular regeneration, and precision medicine. The company was founded by Deepak Srivastava, Benoit G. Bruneau, Bruce R. Conklin, Sheng Ding, Saptarsi Haldar, and Eric Olson in 2016 and is headquartered in South San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hoey TimothyChief Scientific OfficerMar 05 '24Sale7.003,30023,101245,346Mar 06 06:45 PM
Hoey TimothyChief Scientific OfficerFeb 20 '24Sale5.346,56935,046236,146Feb 21 06:05 PM
Tingley WhittemoreChief Medical OfficerFeb 16 '24Sale5.866,50038,09073,534Feb 16 08:35 PM
Ali FarazChief Executive OfficerFeb 16 '24Sale5.866,35837,258113,079Feb 16 08:30 PM
PATTERSON LEONE DChief Fin. and Bus. OfficerFeb 16 '24Sale5.865,20130,47860,755Feb 16 08:32 PM
Hoey TimothyChief Scientific OfficerFeb 16 '24Sale5.864,68127,431242,715Feb 16 08:37 PM
GOEDDEL DAVID VDirectorFeb 12 '24Buy4.502,222,2229,999,99913,599,275Feb 14 04:12 PM
COLUMN GROUP III GP, LP10% OwnerFeb 12 '24Buy4.502,222,2229,999,99913,599,275Feb 14 04:15 PM
Hoey TimothyChief Scientific OfficerAug 29 '23Sale4.267,24330,855247,396Aug 29 06:59 PM
Ali FarazChief Executive OfficerAug 16 '23Sale3.815,56321,195119,437Aug 18 06:31 PM
Tingley WhittemoreChief Medical OfficerAug 16 '23Sale3.815,56321,19576,437Aug 18 06:33 PM
PATTERSON LEONE DChief Fin. and Bus. OfficerAug 16 '23Sale3.814,45216,96264,542Aug 18 06:31 PM
Hoey TimothyChief Scientific OfficerAug 16 '23Sale3.814,00715,267254,639Aug 18 06:34 PM
open in screener | open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2024 FINVIZ.com. All Rights Reserved.